Lung Cancer

James G. Herman, MD, discusses the work that has been done to elucidate biomarkers of response to immunotherapy in non–small cell lung cancer and the necessity of molecular testing at diagnosis.

Anna Chalmers, MD, discusses the PACIFIC trial and how its impact continues to change the treatment paradigm in stage III non-small cell lung cancer.

Katie Kerrigan, MD, a hematology/oncology fellow at Huntsman Cancer Institute, University of Utah School of Medicine, discusses the design and findings of the ongoing phase I PROFILE 1001 trial with crizotinib (Xalkori) in ROS1-mutated non–small cell lung cancer (NSCLC).

Faculty from Huntsman Cancer Institute and Intermountain Healthcare delve into the interesting research efforts being made at their respective institutions.

Lisa A. Cannon-Albright, PhD, discusses her research regarding the heredity of lung cancer, histologic subgroups at increased risk, and the implications these data have on practice.

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the randomized, double-blind, phase III KEYNOTE-189 trial in patients with previously untreated, metastatic nonsquamous non–small cell lung cancer.

Kristen Champion, PhD, FACMG, discusses various molecular testing methods being used in non–small cell lung cancer.

Shiven B. Patel, MD, MBA, FACP, provides insight into key trials in squamous non–small cell lung cancer and how to apply the data to practice.

William T. Sause, MD, discusses various modalities of stage III non–small cell lung cancer treatment and how to effectively select patients for the varying regimens.

Clarke A. Low, MD, discusses the role of osimertinib in EGFR-mutated non–small cell lung cancer and emerging research efforts in the paradigm.

Katie Kerrigan, MD, discusses novel agents emerging in both ROS1- and ALK-mutated non–small cell lung cancer and the sequencing challenges for these patients.